Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN PROJECT: Peg-interferon for CHB with NAFLD
NCT06368882Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Jan 2024
- Primary completion
- Dec 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegylated interferon alpha in Chronic Hepatitis B (CHB) (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: HBsAg clearance at 48 weeks. Started Jan 2024; status: recruiting.
02
Drugs
pegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06368882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06368882.